To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.
文献摘要
Objective Different precision treatment approaches have been proposed for type 2 diabetes, but robust comparisons are lacking. We compared the utility of proposed approaches targeting glucose-lowering therapy in the TriMaster three-way crossover trial. Research design and methods We evaluated four previously reported precision treatment strategies for their ability to predict overall 4-month HbA1c response and within-person differential response to sitagliptin, canagliflozin, and pioglitazone in 309 adults with type 2 diabetes who received all three medications. Approaches included allocation to clusters based on routine features and HOMA, direct outcome prediction using a routine-features treatment-selection model, type 2 diabetes cluster-specific partitioned polygenic scores (PPSs), and a model based on discriminative dimensionality reduction tree (DDRTree) analysis. Results The routine-features model and cluster approach were both strongly associated with overall and differential HbA1c responses (P Conclusions Clinical features are more strongly associated with differential glycemic response than PPS, and direct outcome prediction outperforms data-driven subgrouping for optimizing short-term HbA1c reduction.